| DB ID | MyCo_2154 |
| Title | Serologic responses to pneumocystis proteins in HIV patients with and without Pneumocystis jirovecii pneumonia |
| Year | 2011 |
| PMID | 21372726 |
| Fungal Diseases involved | Pneumocystis pneumonia |
| Associated Medical Condition | HIV-AIDS |
| Genus | Pneumocystis |
| Species | jirovecii |
| Organism | Pneumocystis jirovecii |
| Ethical Statement | All participants signed written informed consent, and the study was approved by the Institutional Review Boards of the University of Cincinnati and the University of Pittsburgh. |
| Site of Infection | Lungs |
| Opportunistic invasive | Opportunistic |
| Sample type | Body fluid |
| Sample source | Serum |
| Host Group | Human |
| Host Common name | Human |
| Host Scientific name | Homo sapiens |
| Biomarker Name | KEX1-IgG |
| Biomarker Full Name | Kexin protein-1 Immuniglobulin-G |
| Biomarker Type | Diagnostic |
| Biomolecule | Protein |
| Geographical Location | Pittsburgh |
| Cohort | Participants were selected from the Multicenter AIDS Cohort Study (MACS). Participants were selected for the following characteristics: occurrence of PcP as first AIDS-defining illness during this period; no participation in a previous study of Msg serology, and having a total of 6 serum specimens available for analysis at 6 month intervals from 18 months before to 18 months after the first episode of PcP. Controls were MACS participants who developed a non-PcP AIDS-defining illness during this period and with three available specimens both before and after the AIDS-defining illness. All participants meeting these criteria were included in the study. |
| Cohort No. | None |
| Age Group | None |
| P Value | None |
| Sensitivity | 0.92 |
| Specificity | 0.21 |
| Positive Predictive Value | 0.57 |
| MIC | None |
| Fold Change | 4 |
| Pathway | None |
| Disease Introduction Mechanism | In HIV-infected individuals, Pneumocystis pneumonia (PcP) remains the most common acquired immune deficiency syndrome (AIDS)-defining illness despite advances in antiretroviral therapy and prophylactic treatment.1,2 PcP is also an unusual, serious complication in non-HIV-infected individuals who are immunosuppressed due to hematologic malignancies, organ transplants, congenital immunodeficiencies, and those receiving specific immunosuppressive drugs such as high dose corticosteroids.3 PcP can also be a complication of treatment with tumor necrosis factor inhibitors.4–8 Although the greatest risk factor for development of PcP is a lack of T-cell related immunity9,10, humoral responses are also of considerable importance, but their role has been less well-studied. |
| Technique | ELISA |
| Analysis Method | ELISA Based |
| ELISA kits | None |
| Assay Data | None |
| Validation Techniques used | ELISA, WESTERN Blot, Proteomics |
| Up Regulation Down Regulation | Decrease |
| Sequence Data | None |
| External Link | None |
